Kohan DE, Barton M. Endothelin and endothelin antagonists in chronic kidney disease. Kidney Int 2014; 86:896–904. doi: 10.1038/ki.2014.143

• PubMed
Kohan DE, Barton M. Endothelin and endothelin antagonists in chronic kidney disease. Kidney Int 2014; 86:896–904. doi: 10.1038/ki.2014.143)| false
• Search Google Scholar
• Export Citation

Raina R, et al. The role of endothelin and endothelin antagonists in chronic kidney disease. Kidney Dis (Basel) 2020; 6:22–34. doi: 10.1159/000504623

• PubMed
Raina R, The role of endothelin and endothelin antagonists in chronic kidney disease. Kidney Dis (Basel) 2020; 6:22–34. doi: 10.1159/000504623)| false
• Search Google Scholar
• Export Citation

Heerspink HJL, et al. Drug-induced reduction in albuminuria is associated with subsequent renoprotection: A meta-analysis. J Am Soc Nephrol 2015; 26:2055–2064. doi: 10.1681/ASN.2014070688

• PubMed
Heerspink HJL, Drug-induced reduction in albuminuria is associated with subsequent renoprotection: A meta-analysis. J Am Soc Nephrol 2015; 26:2055–2064. doi: 10.1681/ASN.2014070688)| false
• Search Google Scholar
• Export Citation

Coresh J, et al. Change in albuminuria and subsequent risk of end-stage kidney disease: An individual participant-level consortium meta-analysis of observational studies. Lancet Diabetes Endocrinol 2019; 7:115–127. doi: 10.1016/S2213-8587(18)30313-9

• PubMed
Coresh J, Change in albuminuria and subsequent risk of end-stage kidney disease: An individual participant-level consortium meta-analysis of observational studies. Lancet Diabetes Endocrinol 2019; 7:115–127. doi: 10.1016/S2213-8587(18)30313-9)| false
• Search Google Scholar
• Export Citation

Fernandez-Fernandez B, et al. Canagliflozin and renal events in diabetes with established nephropathy clinical evaluation and study of diabetic nephropathy with atrasentan: What was learned about the treatment of diabetic kidney disease with canagliflozin and atrasentan? Clin Kidney J 2019; 12:313–321. doi: 10.1093/ckj/sfz070

• PubMed
Fernandez-Fernandez B, Canagliflozin and renal events in diabetes with established nephropathy clinical evaluation and study of diabetic nephropathy with atrasentan: What was learned about the treatment of diabetic kidney disease with canagliflozin and atrasentan? Clin Kidney J 2019; 12:313–321. doi: 10.1093/ckj/sfz070)| false
• Search Google Scholar
• Export Citation

Mann JFE, et al. Avosentan for overt diabetic nephropathy. J Am Soc Nephrol 2010; 21:527–535. doi: 10.1681/ASN.2009060593

• PubMed
Mann JFE, Avosentan for overt diabetic nephropathy. J Am Soc Nephrol 2010; 21:527–535. doi: 10.1681/ASN.2009060593)| false
• Search Google Scholar
• Export Citation

Dhaun N, et al. Selective endothelin-A receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease. Hypertension 2011; 57:772–779. doi: 10.1161/hypertensionaha.110.167486

• PubMed
Dhaun N, Selective endothelin-A receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease. Hypertension 2011; 57:772–779. doi: 10.1161/hypertensionaha.110.167486)| false
• Search Google Scholar
• Export Citation

Heerspink HJL, et al. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): A double-blind, randomised, placebo-controlled trial. Lancet 2019; 393:1937–1947. doi: 10.1016/S0140-6736(19)30772-X

• PubMed
Heerspink HJL, Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): A double-blind, randomised, placebo-controlled trial. Lancet 2019; 393:1937–1947. doi: 10.1016/S0140-6736(19)30772-X)| false
• Search Google Scholar
• Export Citation

Trachtman H, et al. DUET: A phase 2 study evaluating the efficacy and safety of sparsentan in patients with FSGS. J Am Soc Nephrol 2018; 29:2745–2754. doi: 10.1681/ASN.2018010091

• PubMed
Trachtman H, DUET: A phase 2 study evaluating the efficacy and safety of sparsentan in patients with FSGS. J Am Soc Nephrol 2018; 29:2745–2754. doi: 10.1681/ASN.2018010091)| false
• Search Google Scholar
• Export Citation

Hogan J, et al. Complete remission of proteinuria in patients with focal segmental glomerulosclerosis treated with sparsentan, a dual endothelin and angiotensin receptor antagonist, in DUET trial (abstract). American Society of Nephrology (ASN) Annual Meeting (digital) 2020; SU-OR38. https://www.hdcn.com/xk/07or0038.htm

• PubMed
Hogan J, Complete remission of proteinuria in patients with focal segmental glomerulosclerosis treated with sparsentan, a dual endothelin and angiotensin receptor antagonist, in DUET trial (abstract). American Society of Nephrology (ASN) Annual Meeting (digital) 2020; SU-OR38. https://www.hdcn.com/xk/07or0038.htm)| false
• Search Google Scholar
• Export Citation

Komers R, et al. Study design of the phase 3 sparsentan versus irbesartan (DUPLEX) study in patients with focal segmental glomerulosclerosis. Kidney Int Rep 2020; 5:494–502. doi: 10.1016/j.ekir.2019.12.017

• PubMed
Komers R, Study design of the phase 3 sparsentan versus irbesartan (DUPLEX) study in patients with focal segmental glomerulosclerosis. Kidney Int Rep 2020; 5:494–502. doi: 10.1016/j.ekir.2019.12.017)| false
• Search Google Scholar
• Export Citation

Heerspink HJL, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020; 383:1436–1446. doi: 10.1056/NEJMoa2024816

• PubMed
Heerspink HJL, Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020; 383:1436–1446. doi: 10.1056/NEJMoa2024816)| false
• Search Google Scholar
• Export Citation